Synlait (ASX:SM1): You Can’t Fault Management’s Honesty, But Can You Have Hope?

There is a particular kind of corporate announcement that arrives not with spin, but with a kind of exhausted candour, and we saw just this when Synlait issued its 1H26 result yesterday.

“We are not going to attempt to dress things up,” wrote Chair George Adams and CEO Richard Wyeth in their joint letter to shareholders accompanying Synlait’s half-year results. ‘The numbers we are presenting today are frustratingly disappointing,’ they declared.

A striking opening if ever there was one. It was totally stripped of the usual softening language, the caveats about “challenging macro conditions,” the boilerplate reassurances that management is “working hard.” Synlait’s leadership has evidently concluded that the company’s credibility is now more valuable than its dignity, and they are right. The question is whether credibility alone is enough to keep the patient alive while the surgery proceeds.

What are the Best ASX Stocks to invest in right now?

Check our buy/sell tips

Overview of Synlait

Synlait was co-founded by Dr John Penno in 2000. By 2005 it owned eight farms, and in 2007 constructed its first processing plant at Dunsandel in Canterbury’s South Island. In 2010, Chinese dairy giant Bright Dairy took a major stake, and the company listed on the NZX in 2013, adding an ASX listing in 2016. It grew rapidly on the back of booming Chinese demand for premium infant formula, becoming a key manufacturing partner for A2 Milk. This was a crucial relationship: at its peak, it drove the bulk of Synlait’s earnings but also created dangerous customer concentration risk.

The fall

The years that followed were marked by strategic overreach, quality incidents, profit warnings, and a balance sheet that buckled under the weight of capital-intensive expansion. By 2024, it wouldn’t be unfair to describe the company as being in a position of fighting for survival. It was forced to turn to its major shareholders for emergency financial support. Bright Dairy ultimately lifted its stake from 39% to 65.25% via a heavily discounted $185m share issue, while A2 Milk maintained its 19.8% holding, effectively keeping the company solvent.

One of the most significant structural actions in attempts to secure Synlait’s recovery was the sale of its North Island assets to Abbott Laboratories, a long-standing customer since 2020. The deal covers the Pokeno manufacturing facility in North Waikato, a blending and canning facility in Auckland, associated warehousing, inventory and leasehold arrangements for NZ$307m (approximately US$178m).

At Synlait’s November 2025 annual meeting, 99.99% of voting shareholders approved the transaction. Completion is expected on 1 April 2026, with a third-party manufacturing agreement in place so Abbott can continue producing certain base powders at the facilities post-sale. The proceeds were to be directed almost entirely at debt reduction. In one sense, a good thing as it was a critical first step in making Synlait financially viable as a going concern, but sad in that this money would not have been raised otherwise.

Synlait’s results

The headline results for the six months ended 31 January 2026 were stark: a reported EBITDA loss of $34.7m, a reported net loss after tax of $80.6m, and net debt of $472.1m, an increase of 88%. Underlying figures softened the blow slightly, underlying EBITDA of $4.1m and an underlying net loss after tax of $27.3m, but even those figures stripped out the kind of one-off costs that Synlait has now been producing with concerning regularity.

Revenue grew modestly to $949m, up $32.3m, but gross profit collapsed to just $3.1m, a fall of $83.9m. A company that generates nearly a billion dollars in revenue and barely clears three million dollars in gross profit is not running a business; it is running an exercise in industrial endurance.

How a Perfect Storm Forms

The sequence of events that produced this result was, according to management, a “dairy processor’s perfect storm”: not driven by negligence but by a cascading lack of viable choices. It is worth tracing the chain carefully, because it illustrates how quickly operational problems compound in a complex manufacturing environment.

Manufacturing challenges at the Dunsandel facility in the second half of FY25 created an inventory shortfall that required catch-up production in HY26. To focus on that catch-up, Synlait adjusted its manufacturing plan, which left it holding surplus milk, particularly during peak season. Some of the tactical milk sales that followed did not go to plan, forcing Dunsandel teams to pause catch-up production to process the unsold volumes.

Given the dryer configurations at the plant, whole milk powder was then the only ingredient that could be produced. And then, almost perfectly timed to maximise damage, WMP prices fell sharply at the end of CY24 turning the Ingredients portfolio into a loss centre.

Each step in that sequence was a rational response to the step before it. The problem is that the decisions accumulated into an outcome that no single decision-point could have anticipated. Management is emphatic that even with the benefit of hindsight, there is little they could have done differently to improve this result. That may be true – but it also pointed to a structural vulnerability that goes beyond bad luck: Synlait had almost no commercial optionality.

When things went wrong, there were no levers to pull.

The third dimension of the poor result is less dramatic but financially significant: a conservative decision not to recognise further deferred tax assets arising from unused tax losses beyond those already on the books at 31 July 2025.

This was an accounting judgement that reflected the board’s honest assessment of near-term profitability prospects. Namely, not a cash cost but a signal that management does not believe it can confidently project sufficient future taxable income to justify carrying those assets.

The Roadmap: Stabilise, Simplify, Scale

Against this backdrop, Synlait released what it calls its recovery roadmap — three interconnected horizons, delivered at pace: Stabilise, to deliver operational stability and build greater optionality; Simplify, to align priorities and grow high-margin products from existing assets; and Scale, to expand markets, channels, and customer relationships.

The most immediate and tangible action is the sale of the North Island assets, which we alluded to earlier. Chair George Adams confirmed the sale would be on track to complete “next week,” and that it will deliver a stronger and simpler Synlait. The sale includes the company’s Pokeno infant formula facility, which has been a capital-intensive drag, and the Dunsandel-heavy South Island operation will become the company’s entire manufacturing footprint. Importantly, a third-party manufacturing agreement has been agreed upon with Abbott for the production of certain base powders after completion. This ensures some revenue continuity from the divested assets rather than a clean break.

The A2 relationship is also shifting. As A2 transitions volumes to its own Pokeno facility, Synlait will gain manufacturing capacity that has previously been unavailable for business development. The company remains committed to producing A2’s China-label product, registered to be manufactured at Dunsandel. This is actually a potential positive dressed up in the language of transition — freed capacity means Synlait can finally pursue new customers it has been forced to turn away for years.

On the operational side, a new Chief Operating Officer, Rich Hickson, joined in February with a track record in operational transformation and infant formula production, while a new Chief Revenue Officer and a new quality strategy under Chief Quality Officer Hila Mory are also in place. There is a notable emphasis on relocating executive leadership to Canterbury: a symbolic and practical signal that the business is being run from where the product is made, not from a distant corporate floor.

Conclusion: Can It Be Believed?

The honest answer is ‘cautiously’. Synlait is a genuine manufacturer of world-class dairy products with infrastructure that took decades and billions of dollars to build. Its core Dunsandel assets are not impaired — they are underutilised and over-encumbered. The North Island sale, if it proceeds as promised next week, will materially reduce debt and complexity in a single transaction. The new executive team has not yet had time to prove itself, but the appointments are credible.

What Synlait cannot yet offer is a financial recovery timeline. The board has withdrawn full-year guidance for FY26, and the company has explicitly told investors it will only consider growth opportunities once it is confident it can fund and deliver them. That is prudent, but it leaves shareholders navigating a long period without a financial compass.

“The best takeaway from HY26 is that it does not reflect our future,” said Wyeth. It may not. But for now, the future is something Synlait is earning back one decision at a time — and the early decisions, at least, are the right ones.